BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 9764818)

  • 1. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
    Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
    Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
    Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
    Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
    Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Shc docking site on Ret tyrosine kinase.
    Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
    Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
    Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
    J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.
    Durick K; Gill GN; Taylor SS
    Mol Cell Biol; 1998 Apr; 18(4):2298-308. PubMed ID: 9528800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
    Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
    Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells.
    Zhang S; Mantel C; Broxmeyer HE
    J Leukoc Biol; 1999 Mar; 65(3):372-80. PubMed ID: 10080542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.
    Pelicci G; Troglio F; Bodini A; Melillo RM; Pettirossi V; Coda L; De Giuseppe A; Santoro M; Pelicci PG
    Mol Cell Biol; 2002 Oct; 22(20):7351-63. PubMed ID: 12242309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N; Murakami H; Iwashita T; Takahashi M
    J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.